- Home
- NPCT vs IMMX Comparison
NPCT vs IMMX Comparison
Compare NPCT & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NPCT | IMMX |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.2M | 306.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NPCT | IMMX |
|---|---|---|
| Price | $10.49 | $8.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 131.0K | ★ 718.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.82% | N/A |
| EPS Growth | N/A | ★ 14.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.77 | $1.34 |
| 52 Week High | $11.31 | $8.97 |
Technical Indicators
Market Signals| Indicator | NPCT | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 66.27 |
| Support Level | $10.15 | $1.96 |
| Resistance Level | $10.75 | $8.97 |
| Average True Range (ATR) | 0.09 | 0.60 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 20.69 | 83.40 |
Price Performance
Historical ComparisonAbout NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.